(Press-News.org) Contact information: Judy Romero
jromero@crg.org
Cardiovascular Research Foundation
Results of the GIANT trial reported at TCT 2013
Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners
	SAN FRANCISCO, CA – October 31, 2013 – According to a new study, genetic profiling of patients undergoing percutaneous coronary intervention (PCI) may help cardiology teams adjust treatment and improve ischemic outcomes for patients that do not properly metabolize thienopyridine blood thinning therapies such as clopidogrel. 
	Findings from the GIANT trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.  
	The effectiveness of clopidogrel depends on activation to an active metabolite, principally via the CYP2C19 enzymatic pathway. Acute coronary syndrome patients that carry a CYP2C19 gene variant poorly metabolize the drug. These patients are known as slow responders and exhibit a higher one year risk of major ischemic events following PCI. Genetic tests can help identify a patient's CYP2C19 genotype, but it is unknown if on-line adjustment of thienopyridine therapy in the genetically slow-responder patient population may counteract this outcome. 
	The GIANT trial evaluated the clinical impact of CYP2C19 genetic profiling and compliance to an adjusted thienopyridine treatment. The primary endpoint was a composite of death, myocardial infarction, and stent thrombosis after one year in slow responder patients with appropriate therapy after genotyping, compared to non-slow responders. 
	The prospective, multicenter, single arm study enrolled 1,499 patients at the time of primary PCI (onset chest pain < 24 hours). Genetic profiling was performed within 48 hours after intervention to detect a loss of CYP2C19 gene function and identify a resistance to clopidogrel. 
Strong recommendations for treatment adjustment were sent to investigators when patients were identified as slow responders. 
	Dual antiplatelet therapy (DAPT) was prescribed for 12 months after PCI and one year follow up was performed in 96.4 percent of patients (n=1,445) including objective assessment of compliance. A total of 22 percent of patients (n=319) had a profile associated with a CYP2C19 loss of function, known as the slow responder group. The remaining patients constituted the control group. 
	In the slow responder group, 85 percent received an adjusted thienopyridine regimen after the release of the genetic profile. Within the slow responder group, the patients that did receive adjusted therapy experienced fewer adverse events compared to those that did not have adjusted therapy (3.3 percent vs. 15.6 percent, respectively) after one year. Further, the patients that received adjusted therapy experienced a similar rate of adverse events as the control group (3.3 percent vs. 3.04 percent). Poor compliance to treatment was objectively identified in 4.9 percent of patients at one year, and those patients experienced numerically more ischemic events. 
	"Results from the GIANT trial suggest that in patients with acute myocardial infarction treated with primary PCI, identification of a slow response to clopidogrel with subsequent adjustment of treatment leads to similar one year major ischemic event rates to patients with a favorable genetic profile to clopidogrel response," said lead investigator Bernard R. Chevalier, MD from L'Institut CardioVasculaire Paris-Sud in Massy, France. 
	"These findings may help determine alternative treatment strategies for patients identified as CYP2C19 poor metabolizers." 
###
	The GIANT trial was funded by Biotronik. Dr. Chevalier reported receiving research grants/speaker fees or being a consultant for Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik, Colibri, Cook, Cordis, Daichi-Sankyo, Eli-Lilly, Iroko, Medtronic, and Terumo. He is also currently a minor shareholder and director of CERC, a clinical research organization.
	About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
Results of the GIANT trial reported at TCT 2013
Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners
2013-11-01
ELSE PRESS RELEASES FROM THIS DATE:
Percutaneous repair of valve leaks: A new treatment for patients at high risk of cardiac surgery
2013-11-01
Percutaneous repair of valve leaks: A new treatment for patients at high risk of cardiac surgery
PCI repair can mitigate known risks that accompany increases in implanted valves
	MINNEAPOLIS, MN—October 31, 2013—A Paravalvular regurgitation, or leakage, ...
Results of the TATORT-NSTEMI trial presented at TCT 2013
2013-11-01
Results of the TATORT-NSTEMI trial presented at TCT 2013
Removing blood clots during PCI does not improve outcomes compared to standard angioplasty in patients with non-ST-elevation myocardial infarction
	SAN FRANCISCO, CA – OCTOBER 31, 2013 – According to a new study, ...
Results of the REPRISE II trial reported at TCT 2013
2013-11-01
Results of the REPRISE II trial reported at TCT 2013
Second generation transcatheter aortic valve shown to successfully address complications of TAVR
	SAN FRANCISCO, CA – THURSDAY OCTOBER 31, 2013 – In a clinical trial, a second-generation transcatheter aortic valve demonstrated ...
Experimental drug shows encouraging results in treating most common form of lung cancer
2013-11-01
Experimental drug shows encouraging results in treating most common form of lung cancer
	An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small ...
Oligomeric proanthocyanidin suppresses the death of retinal ganglion cells
2013-11-01
Oligomeric proanthocyanidin suppresses the death of retinal ganglion cells
	
The death of retinal ganglion cells is a hallmark of many optic neurodegenerative diseases such as glaucoma and retinopathy. Oxidative stress is one of the major reasons to cause the ...
Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury?
2013-11-01
Can Aβ worsen cognitive impairment following cerebral ischemia-reperfusion injury?
	
Amyloid β-peptide, a major component of senile plaques in Alzheimer's disease, has been impli-cated in neuronal cell death and cognitive impairment. Recently, studies ...
Low-frequency rTMS prevents chronic epileptic seizure
2013-11-01
Low-frequency rTMS prevents chronic epileptic seizure
	Although increasing evidence indicates that low-frequency repetitive transcranial magnetic stimulation (rTMS), an emerging technology for neural regulation, has antiepileptic effects, the mechanism remains unclear. ...
Exposure to cortisol-like medications before birth may contribute to emotional problems and brain changes
2013-11-01
Exposure to cortisol-like medications before birth may contribute to emotional problems and brain changes
Reports new study in Biological Psychiatry
	Philadelphia, PA, October 31, 2013 – Neonatologists seem to perform miracles in the fight to support the survival of ...
JCI early table of contents for Nov. 1, 2013
2013-11-01
JCI early table of contents for Nov. 1, 2013
	Liver tropism is key for B cell deletion immunotherapy 
	Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding ...
Liver tropism is key for B cell deletion immunotherapy
2013-11-01
Liver tropism is key for B cell deletion immunotherapy
	Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other ...
LAST 30 PRESS RELEASES:
Cobalt single atom-phosphate functionalized reduced graphene oxide/perylenetetracarboxylic acid nanosheet heterojunctions for efficiently photocatalytic H2O2 production
World-first study shows Australian marsupials contaminated with harmful ‘forever chemicals’
Unlocking the brain’s hidden drainage system
Enhancing smoking cessation treatment for people living with HIV
Research spotlight: Mapping how gut neurons respond to bacteria, parasites and food allergy
Gordon and Betty Moore Foundation Experimental Physics Investigators awards to UCSB experimentalists opens the door to new insights and innovations
Meerkats get health benefit from mob membership
COVID-19 during pregnancy linked to higher risk of neurodevelopmental disorders in children
How a chorus of synchronized frequencies helps you digest your food
UAlbany researcher partners on $1.2 million NSF grant to explore tropical monsoon rainfall patterns
Checkup time for Fido? Wait might be longer in the country
Genetic variation impact scores: A new tool for earlier heart disease detection
The Lundquist Institute awarded $9 million to launch Community Center of Excellence for Regenerative Medicine
'Really bizarre and exciting': The quantum oscillations are coming from inside
Is AI becoming selfish?
New molten salt method gives old lithium batteries a second life
Leg, foot amputations increased 65% in Illinois hospitals between 2016-2023
Moffitt studies uncover complementary strategies to overcome resistance to KRAS G12Cinhibitors in lung cancer
National summit of experts charts unprecedented roadmap to reduce harms from firearms in new ways
Global environmental DNA (eDNA) surveys significantly expand known geographic and ecological niche ranges of marine fish, highlighting current biases in conservation and ecological modeling
Hundreds of animal studies on brain damage after stroke flagged for problematic images
Prize winner’s research reveals how complex neural circuits are correctly wired during brain development
Supershear rupture sustained in thick fault zone during 2025 Mandalay earthquake, study in research package shows
Study reveals how brain cell networks stabilize memory formation
CTE: More than just head trauma, suggests new study
New psychology study suggests chimpanzees might be rational thinkers
Study links genetic variants to higher 'bad' cholesterol and heart attack risk
Myanmar fault had ideal geometry to produce 2025 supershear earthquake
Breakthrough in BRCA2 research: a novel mechanism behind chemoresistance discovered
New funding for health economics research on substance use disorder treatments
[Press-News.org] Results of the GIANT trial reported at TCT 2013Genetic profiling may provide clinical benefit by identifying heart attack patients that are resistant to blood thinners